This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
by Kinjel Shah
The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.
Novo Nordisk (NVO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $192.87, marking a +0.12% move from the previous day.
Novo Nordisk (NVO) Announces Stock Split to Enhance Liquidity
by Zacks Equity Research
Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.
Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie
by Zacks Equity Research
Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.
"Blockbuster Status": 3 Bios to Buy and Hold
by Andrew Rocco
The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
by Zacks Equity Research
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, Booking Holdings, Sony and EOG
by Zacks Equity Research
Microsoft, Novo Nordisk, Booking Holdings, Sony and EOG are included in this Analyst Blog.
Top Stock Reports for Microsoft, Novo Nordisk & Booking Holdings
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and Booking Holdings Inc. (BKNG).
Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $195.40, marking a +0.01% move from the previous day.
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
by Zacks Equity Research
Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.
Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
10 Drugs Selected for Medicare Price Reduction
by Zacks Equity Research
10 Drugs Selected for Medicare Price Reduction
Medicare Drugs Targeted Under Inflation Reduction Act
by Mark Vickery
Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.
Beat the Market Like Zacks: Hubbell, Adobe, Nikola in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
by Zacks Equity Research
Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
These 3 Large-Cap Pharma Stocks Have Been Red-Hot
by Derek Lewis
Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now
by Zacks Equity Research
J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
by Zacks Equity Research
Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.
3 Buy-Rated Stocks Displaying Notable Price Strength
by Derek Lewis
Several stocks, including these three, have all delivered double-digit percentage gains over the last month, widely outperforming the general market. Sporting improved outlooks, can they continue climbing?
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.
The Zacks Analyst Blog Highlights Visa, Novo Nordisk, Medtronic, Shopify and Colgate-Palmolive
by Zacks Equity Research
Visa, Novo Nordisk, Medtronic, Shopify and Colgate-Palmolive are included in this Analyst Blog.